LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET plus ) non-small cell lung cancer (NSCLC)

被引：2
|
作者：
Loong, H. H. F. [1 ]
Goto, K. [2 ]
Elamin, Y. Y. [3 ]
Solomon, B. [4 ]
Santini, F. C. [5 ]
Soldatenkova, V. [6 ]
Sashegyi, A. [6 ]
Lin, A. Bence [6 ]
Lin, B. K. [6 ]
Wolf, J. [7 ]
Oxnard, G. R. [8 ]
Zhou, C. [9 ]
Drilon, A. [10 ]
Park, K. [11 ]
机构：
[1] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Peoples R China
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[4] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[5] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil
[6] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[7] Univ Hosp Cologne, Oncol, Cologne, Germany
[8] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[9] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
[10] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Early Drug Dev Serv, New York, NY USA
[11] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Div Heamatol Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1727
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1413TiP
引用
收藏
页码：S893 / S893
页数：1
相关论文
共 50 条
  • [31] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Gao, Ming
    Zhang, Xia
    Yan, Huan
    Sun, Decong
    Yang, Xuejiao
    Yuan, Fang
    Ju, Yanfang
    Wang, Lijie
    Wang, Jinliang
    Zhao, Wei
    Zhang, Dong
    Li, Lin
    Xu, Xiaoyun
    Ma, Junxun
    Hu, Yi
    Zhang, Xiaotao
    [J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
  • [32] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Ming Gao
    Xia Zhang
    Huan Yan
    Decong Sun
    Xuejiao Yang
    Fang Yuan
    Yanfang Ju
    Lijie Wang
    Jinliang Wang
    Wei Zhao
    Dong Zhang
    Lin Li
    Xiaoyun Xu
    Junxun Ma
    Yi Hu
    Xiaotao Zhang
    [J]. Supportive Care in Cancer, 2023, 31
  • [33] LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET plus ) NSCLC.
    Goldman, Jonathan W.
    Sands, Jacob
    Hallqvist, Andreas
    Kim, Hye Ryun
    Li, Guoping
    Wu, Lin
    Su, Weiji
    Bayt, Theresa
    Yang, Xue-Ning
    Hochmair, Maximilian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study
    Gainor, J.
    Curigliano, G.
    Doebele, R. C.
    Lin, J. J.
    Ou, S. -H.
    Miller, S.
    Turner, C. D.
    Subbiah, V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S5 - S5
  • [35] The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
    Ke, Jun-yi
    Huang, Shu
    Jing, Zhi-tao
    Duan, Min-chao
    [J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 768 - 776
  • [36] The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
    Jun-yi Ke
    Shu Huang
    Zhi-tao Jing
    Min-chao Duan
    [J]. Investigational New Drugs, 2023, 41 : 768 - 776
  • [37] Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer
    Wan, Rui
    Li, Weihua
    Wang, Zhijie
    Zhong, Jia
    Lin, Lin
    Duan, Jianchun
    Wang, Jie
    [J]. HELIYON, 2024, 10 (02)
  • [38] Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
    Lu, Shun
    Cheng, Ying
    Huang, Dingzhi
    Sun, Yuping
    Wu, Lin
    Zhou, Chengzhi
    Guo, Ye
    Shao, Jingxin
    Zhang, Wanli
    Zhou, Jianying
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [39] Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion plus non-small cell lung cancer (NSCLC)
    Gautschi, O.
    Drilon, A.
    Tan, D. S. W.
    Oxnard, G. R.
    McCoach, C.
    Goto, K.
    Park, K.
    Alonso Casal, G.
    de Braud, F.
    French, P.
    Soldatenkova, V.
    Besse, B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S835 - S835
  • [40] Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study
    Drilon, A. E.
    Chan, J.
    Sands, J.
    Tan, D. S. W.
    Weiss, J.
    Solomon, B.
    Kim, Y. J.
    Johnson, M. L.
    Puri, T.
    Sarno, M. A.
    Kang, S.
    Soldatenkova, V.
    Duann, C-W.
    Szymczak, S.
    Subbiah, V.
    Besse, B.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S999 - S999
12345